The survival after recurrence of colorectal cancer: a retrospective study focused on time to recurrence after curative resection

Surgery Today ◽  
2021 ◽  
Author(s):  
Hirotaka Furuke ◽  
Tomohiro Arita ◽  
Yoshiaki Kuriu ◽  
Hiroki Shimizu ◽  
Jun Kiuchi ◽  
...  
2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.


2021 ◽  
Vol 93 (6) ◽  
pp. AB86
Author(s):  
Hirohito Tanaka ◽  
Shiko Kuribayashi ◽  
Masanori Sekiguchi ◽  
Atsuo Iwamoto ◽  
Yoko Hachisu ◽  
...  

Author(s):  
T.J. Kruser ◽  
S.T. Chao ◽  
P. Elson ◽  
G.H. Barnett ◽  
M. Vogelbaum ◽  
...  

2007 ◽  
Vol 50 (11) ◽  
pp. 1783-1799 ◽  
Author(s):  
Joe J. Tjandra ◽  
Miranda K. Y. Chan

Sign in / Sign up

Export Citation Format

Share Document